Our data suggest that FGF-21 might be a promising marker for risk stratification to facilitate identification of high-risk candidates in whom initiation of CRC screening at younger ages or more intensive CRC screening might be warranted. This evidence concerns the gene FGF21 and colorectal carcinoma.